Antares Pharma Cmn (ATRS) 1.03 $ATRS How These

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Antares Pharma Cmn (ATRS) 1.03 $ATRS

How These Healthcare Stocks are Performing? -- Antares Pharma, Insulet, Globus Medical, and NuVasive
PR Newswire - Wed Jul 27, 7:20AM CDT
Ahead of today's trading session, Stock-Callers.com shifts focus on the Healthcare sector, which is known for its resiliency during downturns. However, current economic conditions are making it difficult for operators to manage their resources and keep up with the increasing demands. We take a look at this morning's picks and assess their performances at the close on Tuesday, July 26, 2016: Antares Pharma Inc. (NASDAQ: ATRS), Insulet Corp. (NASDAQ: PODD), Globus Medical Inc. (NYSE: GMED), and NuVasive Inc. (NASDAQ: NUVA). Learn more about these stocks by accessing their freenotes at:
PODD: 35.38 (-0.01), GMED: 23.49 (+0.54), NUVA: 63.29 (+1.09), ATRS: 1.03 (+0.03)

What Investors are Making of These Healthcare Stocks? - Antares Pharma, Globus Medical, NuVasive, and Insulet
PR Newswire - Fri Jun 24, 6:49AM CDT
Since the financial crisis, the Healthcare sector has proven to be defensive against market downturns, continuing to present opportunities for growth. Today's featured companies on Stock-Callers.com belong in this arena: Antares Pharma Inc. (NASDAQ: ATRS), Globus Medical Inc. (NYSE: GMED), NuVasive Inc. (NASDAQ: NUVA), and Insulet Corp. (NASDAQ: PODD). Learn more about these stocks and receive your complimentary trade alerts at:
PODD: 35.38 (-0.01), GMED: 23.49 (+0.54), NUVA: 63.29 (+1.09), ATRS: 1.03 (+0.03)

Antares Pharma Announces Settlement of Patent Litigation for Key Alliance Business Product
GlobeNewswire - Thu Jun 23, 9:54AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Teva Pharmaceuticals USA, Inc. has settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC (AstraZeneca) relating to AstraZeneca's US Patent Nos. 6,858,576, 6,872,700, 6,956,026, 7,297,761, 6,902,744, 7,521,423, and 7,741,269 and AstraZeneca's BYETTA (exenatide), and entered into a settlement and license agreement with AstraZeneca, pursuant to which AstraZeneca granted a license to Teva to manufacture and commercialize the generic version of BYETTA described in Teva's ANDA No. 205984 in the United States.
ATRS: 1.03 (+0.03)

Medical Device Leader Series: Top Needle-Free Injection Device Developers, Manufacturers and Marketers in 2016
PR Newswire Europe - Tue Jun 21, 8:02AM CDT
LONDON, June 21, 2016 /PRNewswire/ --
ATRS: 1.03 (+0.03)

Antares Pharma to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 8:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 4:30 p.m. Eastern Time.
ATRS: 1.03 (+0.03)

Antares Pharma Announces Update to QuickShot Testosterone Clinical Program
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the last patient has completed treatment in a dose-blinded, multiple-dose, concentration controlled 26-week safety and pharmacokinetic phase 3 study of QuickShot(R) Testosterone (QS T) administered subcutaneously once each week to adult males with hypogonadism. The study, QST-15-005 included a screening phase, a titration phase and a treatment phase for evaluation of safety and tolerability assessments, including laboratory assessments, adverse events and injection site assessments. The study was conducted to help ensure that we satisfy the U.S. Food and Drug Administration's recommendation that we have a safety database of approximately 350 subjects exposed to QS T in total with approximately 200 subjects exposed for six months and approximately 100 subjects exposed for a year.
ATRS: 1.03 (+0.03)

Antares Pharma reports 1Q loss
Automated Insights - Mon May 09, 6:08AM CDT
EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Monday reported a loss of $7.7 million in its first quarter.
ATRS: 1.03 (+0.03)

Antares Pharma To Host First Quarter Operating And Financial Results Conference Call
GlobeNewswire - Mon May 02, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release its first quarter 2016 financial results and recent operating progress before the market opens on Monday, May 9, 2016, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Robert F. Apple, President and Chief Executive Officer will host the call.
ATRS: 1.03 (+0.03)

New Strong Sell Stocks for April 28th
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
CAVM: 47.24 (+0.57), CMG: 414.08 (-9.91), SAM: 182.16 (-0.72), DOV: 69.93 (-1.50), ATRS: 1.03 (+0.03)

Antares Pharma to Present at the Deutsche Bank Securities, Inc. 41st Annual Health Care Conference
GlobeNewswire - Wed Apr 27, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert Apple, President and Chief Executive Officer, will present at the Deutsche Bank Securities, Inc. 41 Annual Health Care Conference on Wednesday May 4, 2016 at 9:20 am Eastern Time.
DB: 13.07 (-0.37), ATRS: 1.03 (+0.03)

OTREXUP.COM Website Awarded a Bronze Horizon Interactive Award
GlobeNewswire - Mon Apr 25, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the Company's OTREXUP.COM website has been awarded a 2015 Bronze Horizon Interactive Award in the category of Consumer Information Websites. The Horizon Interactive Awards are among the most prestigious awards in the field of interactive and creative media. The annual international competition, now in its 14 season, recognizes, promotes and awards the best web sites, videos, online advertising, print media and mobile applications. In 2015 alone, Horizon received over 1,100 competition submissions from more than 40 countries. A volunteer panel of industry professionals review the entries to determine the recognition and shed a spotlight on the winners and the people who made it happen.
ATRS: 1.03 (+0.03)

4 Trending Small Cap Stocks Making Big Moves Today
ACCESSWIRE - Fri Apr 22, 9:12AM CDT
NEW YORK, NY / ACCESSWIRE / April 22, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. EBIO, EXXI, SUNE and ATRS are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
EXXI: 0.13 (-0.01), EBIO: 3.80 (-0.17), SUNE: 0.34 (unch), ATRS: 1.03 (+0.03)

Antares Pharma Discloses "Pen 1" Development Project as Teriparatide
GlobeNewswire - Tue Apr 05, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today disclosed that the "Pen 1" development project with Teva Pharmaceutical Industries, Ltd. (Teva) relates to a generic form of Forteo (teriparatide [rDNA origin] injection) (Teriparatide), marketed by Eli Lilly and Company (Lilly). Forteo is an injectable treatment for osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid induced osteoporosis in men and postmenopausal women. On March 16, 2016 Lilly filed a lawsuit against Teva in response to Teva's Paragraph IV notice and filing contained in their Abbreviated New Drug Application (ANDA) for Teriparatide filed with, and accepted by, the U.S. Food and Drug Administration (FDA). Based on available information, Antares believes that Teva may be the "first applicant" to file an ANDA for a generic equivalent of Forteo and, should Teva's ANDA be approved, may be entitled to 180 days of generic market exclusivity.
ATRS: 1.03 (+0.03)

New Strong Sell Stocks for March 31st
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 7:37AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AXE: 59.46 (-1.82), ALIM: 2.08 (+0.03), AMD: 6.64 (-0.22), CWT: 33.97 (+0.24), ATRS: 1.03 (+0.03)

New Strong Sell Stocks for March 29th
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:07AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
CRME: 3.13 (unch), ACAS: 16.50 (+0.03), ATTU: 9.43 (-0.32), CWT: 33.97 (+0.24), ATRS: 1.03 (+0.03)

Additional Dosage Strengths of Otrexup(TM) (methotrexate) Injection Approved by FDA
GlobeNewswire - Tue Mar 29, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced the approval by the U.S. Food and Drug Administration (FDA) of three new dosage strengths of OTREXUP (methotrexate) injection. The new dosage strengths of 12.5 mg/0.4 ml, 17.5 mg/0.4 ml and 22.5 mg/0.4 ml will complement the already approved and marketed strengths of 7.5 mg/0.4 ml, 10 mg/0.4 ml, 15 mg/0.4 ml, 20 mg/0.4 ml, and 25 mg/0.4 ml. New, interim dose-strength options will enable physicians to select more specific, optimal doses to help achieve patient treatment goals.
ATRS: 1.03 (+0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 112

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Stand Takes Colorado Bet on Wildfire-Smart Coverage

Updated Category News Views 164

Colorado’s insurance mess has finally attracted a company willing to price the driveway, the vents, and the tree line instead of shrugging at an entire ZIP code. Stand has launched homeowners coverage across the state, including mountain communities where wildfire exposure has made insurance both costly and scarce. This is not a small problem dressed up with a shiny...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 175

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 120

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 129

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 16

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 83

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 69

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 197

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 228

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading

Top 5 Most Recently Viewed Articles

Microvast Welcomes New CFO Pat Schultz to Drive Growth

Updated Category News Views 460

Microvast Holdings, Inc. Welcomes Pat Schultz as Chief Financial Officer Microvast Holdings, Inc. (NASDAQ: MVST), a prominent name in advanced battery technologies, has announced a significant change in its executive leadership team. The company is excited to introduce Carl T “Pat” Schultz as its new Chief Financial Officer. Pat Schultz's Impressive Background With...

Continue Reading
Cipla Faces Lanreotide Shortage: UBS Maintains Buy Rating

Updated Category News Views 536

UBS Adjusts Cipla's Price Target Amid Lanreotide Challenges Recent developments have placed Cipla Ltd. (CIPLA:IN) in the spotlight as UBS has decided to maintain its Buy rating on the company's shares, albeit with a notable revision. The price target has been decreased from INR2,060.00 to INR1,960.00, reflecting anticipated challenges due to a shortage of Lanreotide, an...

Continue Reading
Innovative Strategies at GovFin 2025 for Financial Progress

Updated Category News Views 197

GovFin 2025: Shaping the Future of Financial Reporting GovFin 2025 brings together leading minds to discuss the transformation of municipal bond issuance and the Financial Data Transparency Act (FDTA). With nine agencies preparing to finalize the first phase of FDTA rulemaking, expectations are high. Each agency will devise proposals for their own data collection...

Continue Reading
Broadway Licensing Unveils Festive Musical Holiday Showcase

Updated Category News Views 166

Broadway Licensing Introduces a Joyous Holiday Production Broadway Licensing, the prominent musical imprint of Broadway Licensing Global, is thrilled to share the launch of its latest holiday musical, Christmas in Connecticut. This enchanting show brings to life the beloved 1945 Warner Bros. Pictures film through its contemporary adaptation. Overview of the Musical's...

Continue Reading
Innovative Quick Connect Device Revolutionizes Electrical Installations

Updated Category News Views 198

Innovative Electrical Fixture Quick Connect Device In a world where electrical installations can be complicated and time-consuming, one inventor has sought to simplify this process significantly. The Electrical Fixture Quick Connect Device is designed to transform how lighting fixtures are connected to electrical networks. The vision behind this invention is...

Continue Reading